 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...185186187188189190191192193194195...235236» |
- ||| AL101 / Ayala Pharma
Trial completion, Enrollment change, Combination therapy, Metastases: Study to Evaluate Safety & Tolerability of BMS-906024 in Combination With Chemotherapy & to Define DLTs & MTD of BMS-906024 in Combination With One of the Following Chemotherapy Regimens; Weekly Paclitaxel, 5FU+Irinotecan or Carboplatin+Paclitaxel in Subjects With Advanced / Metastatic Solid Tumors (clinicaltrials.gov) - Dec 19, 2017
P1, N=141, Completed, Sponsor: Bristol-Myers Squibb
Active, not recruiting --> Completed | N=95 --> 141 | Active, not recruiting --> Completed | N=95 --> 141 | Active, not recruiting --> Completed | N=95 --> 141
- | Avastin (bevacizumab) / Roche
Enrollment closed, Metastases: BeTRI: Bevacizumab + Triplet Treatment for Untreated With Chemotherapy Metastatic Colorectal Cancer (clinicaltrials.gov) - Dec 19, 2017
P2, N=45, Active, not recruiting, Sponsor: Translational Research Informatics Center, Kobe, Hyogo, Japan
Active, not recruiting --> Completed | N=95 --> 141 | Active, not recruiting --> Completed | N=95 --> 141 | Active, not recruiting --> Completed | N=95 --> 141 Recruiting --> Active, not recruiting
- ||||| AiTan (rivoceranib) / HLB Bio Group
New P2 trial, Real-world evidence, Real-world, Metastases: Apatinib Treatment as the Neoadjuvant Therapy in Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 18, 2017
P2, N=100, Not yet recruiting, Sponsor: Sichuan Provincial People's Hospital
- | veliparib (ABT-888) / AbbVie
Enrollment closed, PARP Biomarker: S1513: FOLFIRI or Modified FOLFIRI and Veliparib as Second Line Therapy in Treating Patients With Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 18, 2017
P2, N=143, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| epacadostat (INCB024360) / Incyte
Enrollment change, Metastases: A Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Participants With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) (clinicaltrials.gov) - Dec 18, 2017
P1/2, N=421, Recruiting, Sponsor: Incyte Corporation
Recruiting --> Active, not recruiting N=332 --> 421
- | Trial primary completion date, Metastases: SYLT: POF Versus FOLFOX Versus FOLFOX Plus ip Paclitaxel in AGC (clinicaltrials.gov) - Dec 15, 2017
P2, N=90, Enrolling by invitation, Sponsor: Fujian Cancer Hospital
N=332 --> 421 Trial primary completion date: Sep 2017 --> Sep 2019
- | branebrutinib (BMS-986195) / BMS
Trial completion, Enrollment change, Trial primary completion date: Effects of Concomitant Administration of BMS-986195 on Methotrexate, Caffeine, Montelukast, Flurbiprofen, Omeprazole, Midazolam, Digoxin, and Pravastatin (clinicaltrials.gov) - Dec 15, 2017
P1, N=26, Completed, Sponsor: Bristol-Myers Squibb
Trial primary completion date: Sep 2017 --> Sep 2019 Not yet recruiting --> Completed | N=12 --> 26 | Trial primary completion date: Jun 2017 --> Nov 2017
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date, Trial primary completion date: Phase I Study of the Combination of Apatinib and POF (clinicaltrials.gov) - Dec 15, 2017
P1, N=9, Not yet recruiting, Sponsor: Fujian Cancer Hospital
Not yet recruiting --> Completed | N=12 --> 26 | Trial primary completion date: Jun 2017 --> Nov 2017 Initiation date: Aug 2017 --> Jan 2018 | Trial primary completion date: Aug 2018 --> Dec 2018
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
New P2 trial, Combination therapy, Metastases: CPI-613 in Combination With Modified FOLFIRINOX in Patients With Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 14, 2017
P2, N=45, Not yet recruiting, Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University
- ||| Keytruda (pembrolizumab) / Merck (MSD)
New P1 trial, Metastases: Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) (clinicaltrials.gov) - Dec 14, 2017
P1b, N=220, Not yet recruiting, Sponsor: Merck Sharp & Dohme Corp.
- | Keytruda (pembrolizumab) / Merck (MSD)
Enrollment open, PD(L)-1 Biomarker, Surgery, Metastases: Pembrolizumab, Combination Chemotherapy, and Radiation Therapy Before Surgery in Treating Adult Patients With Locally Advanced Gastroesophageal Junction or Gastric Cardia Cancer That Can Be Removed by Surgery (clinicaltrials.gov) - Dec 14, 2017
P1b/2, N=68, Recruiting, Sponsor: Mayo Clinic
Initiation date: Aug 2017 --> Jan 2018 | Trial primary completion date: Aug 2018 --> Dec 2018 Suspended --> Recruiting
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: AALL1331: Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 13, 2017
P3, N=598, Recruiting, Sponsor: National Cancer Institute (NCI)
Suspended --> Recruiting Trial primary completion date: Apr 2018 --> Mar 2022
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Trial primary completion date, Metastases: BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial (clinicaltrials.gov) - Dec 13, 2017
P2, N=50, Recruiting, Sponsor: howard safran
Trial primary completion date: Apr 2018 --> Mar 2022 Trial primary completion date: Sep 2017 --> Sep 2018
- | Epratucyn (epratuzumab) / Gilead
Trial completion: Chemoimmunotherapy With Epratuzumab in Relapsed Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Dec 12, 2017
P2, N=134, Completed, Sponsor: Children's Oncology Group
Trial primary completion date: Sep 2017 --> Sep 2018 Active, not recruiting --> Completed
- | thioguanine / Generic mfg., nelarabine / Generic mfg.
Trial primary completion date: AALL0434: Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Dec 12, 2017
P3, N=1895, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Trial primary completion date: Aug 2013 --> Sep 2017
- | 5-fluorouracil / Generic mfg., metformin / Generic mfg., leucovorin calcium / Generic mfg.
Enrollment closed, Metastases: Metformin Plus Modified FOLFOX 6 in Metastatic Pancreatic Cancer (clinicaltrials.gov) - Dec 12, 2017
P2, N=50, Active, not recruiting, Sponsor: Case Comprehensive Cancer Center
Trial primary completion date: Aug 2013 --> Sep 2017 Recruiting --> Active, not recruiting
- | Trial completion, Enrollment change, Metastases: Genetic Analysis-Guided Dosing of FOLFIRABRAX in Treating Patients With Advanced Gastrointestinal Cancer (clinicaltrials.gov) - Dec 12, 2017
P1/2, N=19, Completed, Sponsor: University of Chicago
Recruiting --> Active, not recruiting Recruiting --> Completed | N=51 --> 19
- | varlitinib (ASLAN001) / ASLAN Pharma
Enrollment open, Combination therapy, Metastases: Varlitinib in Combination With mFOLFOX6 for Advanced or Metastatic Gastric Cancer (First Line) (clinicaltrials.gov) - Dec 11, 2017
P2/3, N=40, Recruiting, Sponsor: Aslan Pharmaceuticals
Recruiting --> Completed | N=51 --> 19 Not yet recruiting --> Recruiting
- ||||| dilpacimab (ABT-165) / AbbVie
New P2 trial, Metastases: A Study of ABT-165 Plus FOLFIRI vs Bevacizumab Plus FOLFIRI in Subjects With Metastatic Colorectal Cancer Previously Treated With Fluoropyrimidine, Oxaliplatin and Bevacizumab (clinicaltrials.gov) - Dec 10, 2017
P2, N=100, Not yet recruiting, Sponsor: AbbVie
- | Blincyto (blinatumomab) / Astellas, Amgen
Trial primary completion date: ECOG-ACRIN E1910: Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia (clinicaltrials.gov) - Dec 8, 2017
P3, N=360, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Trial primary completion date: Jun 2018 --> Jun 2021
- | Avastin (bevacizumab) / Roche
Trial completion, Trial primary completion date, Metastases: MOMA: Maintenance Bevacizumab Only or Bevacizumab Plus Metronomic Chemotherapy in Advanced Colorectal Cancer (clinicaltrials.gov) - Dec 7, 2017
P2, N=232, Completed, Sponsor: Azienda Ospedaliero, Universitaria Pisana
Trial primary completion date: Jun 2018 --> Jun 2021 Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Mar 2017
- | EGFR bi-armed autologous activated T cells / Barbara Ann Karmanos Cancer Institute
Enrollment closed, Enrollment change, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker, IO biomarker, Metastases: NCI-2015-01942: BATS With in Combination With Low Dose IL-1 and GM-CSF for Advanced Pancreatic Cancer (clinicaltrials.gov) - Dec 7, 2017
P1/2, N=2, Active, not recruiting, Sponsor: Barbara Ann Karmanos Cancer Institute
Recruiting --> Completed | Trial primary completion date: Jun 2015 --> Mar 2017 Suspended --> Active, not recruiting | N=43 --> 2 | Trial primary completion date: Dec 2016 --> Dec 2018
- | AiTan (rivoceranib) / HLB Bio Group
New P3 trial: mFOLFOX6 Chemotherapy With Apatinib as Postoperative Treatment in Stage IIIB or IIIC Colorectal Cancer (clinicaltrials.gov) - Dec 7, 2017
P3, N=300, Recruiting, Sponsor: Huashan Hospital
- Enrollment change, Combination therapy, Metastases: PanCO: A Pilot Study of OncoSil (clinicaltrials.gov) - Dec 5, 2017
P=N/A, N=40, Recruiting, Sponsor: OncoSil Medical Limited
Suspended --> Active, not recruiting | N=43 --> 2 | Trial primary completion date: Dec 2016 --> Dec 2018 N=20 --> 40
- |||||||||| Erbitux (cetuximab) / Eli Lilly
Biomarker, New P3 trial: PETACC-8 miR-31-3p and miR-31-5p Ancillary Study (clinicaltrials.gov) - Dec 5, 2017
P3, N=1808, Completed, Sponsor: IntegraGen SA
- ||||| Bavencio (avelumab) / EMD Serono
Enrollment closed, Metastases: Avelumab in First-Line Maintenance Gastric Cancer (JAVELIN Gastric 100) (clinicaltrials.gov) - Dec 4, 2017
P3, N=466, Active, not recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
N=20 --> 40 Recruiting --> Active, not recruiting
- | pyrimethamine / Generic mfg.
Trial completion: Phase I Study of Pyrimethamine in Healthy Japanese and Caucasian Subjects (clinicaltrials.gov) - Dec 4, 2017
P1, N=14, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Recruiting --> Completed
- | Nexavar (sorafenib) / Bayer, Amgen
Review, Journal: Optimal therapy for patients with hepatocellular carcinoma and resistance or intolerance to sorafenib: challenges and solutions. (Pubmed Central) - Dec 1, 2017
Multi-target kinase inhibitors such as lenvantinib and regorafenib have recently met their primary endpoints as first- and second-line therapy, respectively, with regorafenib now representing the only FDA-approved drug for second-line treatment of HCC...Immunotherapy is an interesting area of research in the treatment of HCC with preclinical and early clinical data demonstrating exciting results; thus numerous investigational studies are currently focusing on immunotherapy in the treatment of HCC. While systemic treatment options in HCC remain a challenge for providers, in this review, we summarize the current literature and highlight areas of progress with respect to the treatment of patients with HCC and resistance or intolerance to sorafenib.
- conatumumab (AMG 655) / Amgen
Trial primary completion date: Open Label Extension Study of Conatumumab and Ganitumab (AMG 479) (clinicaltrials.gov) - Nov 30, 2017
P2, N=12, Active, not recruiting, Sponsor: Amgen
While systemic treatment options in HCC remain a challenge for providers, in this review, we summarize the current literature and highlight areas of progress with respect to the treatment of patients with HCC and resistance or intolerance to sorafenib. Trial primary completion date: Jan 2018 --> Jul 2018
- Erbitux (cetuximab) / Eli Lilly
Biomarker, Trial primary completion date, Metastases: Biomarker Directed Treatment in Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 27, 2017
P2, N=30, Recruiting, Sponsor: Arbeitsgemeinschaft medikamentoese Tumortherapie
Trial primary completion date: Jan 2018 --> Jul 2018 Trial primary completion date: Aug 2016 --> Aug 2018
- | otilimab (GSK3196165) / GSK
Trial completion, Combination therapy: Mechanistic Study of GSK3196165 Plus Methotrexate (MTX) in Subjects With Active Rheumatoid Arthritis (clinicaltrials.gov) - Nov 27, 2017
P2a, N=39, Completed, Sponsor: GlaxoSmithKline
Trial primary completion date: Aug 2016 --> Aug 2018 Active, not recruiting --> Completed
- ||| Enrollment closed, Metastases: POLAF: Phase II Trial to Assess FOLFIRI+Aflibercept Efficacy in Patients With Oxaliplatin-pretreated Metastatic Colorectal Cancer With or Without ACE Polymorphisms (clinicaltrials.gov) - Nov 27, 2017
P2, N=100, Active, not recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||| Enrollment open, Metastases: AFEMA: Study to Assess the Efficacy and Safety of Treatment With FOLFIRI-aflibercept Compared to Initial Treatment With FOLFIRI-aflibercept (for 6 Cycles) Followed by Maintenance With 5FU-aflibercept, in an Elderly Population With mCRC After Failure of an Oxaliplatin-based Regimen (clinicaltrials.gov) - Nov 27, 2017
P2, N=168, Recruiting, Sponsor: Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- || ipatasertib (RG7440) / Roche
Trial primary completion date, Combination therapy, Metastases: Safety and Clinical Pharmacology of GDC-0068 in Combination With Docetaxel, Fluoropyrimidine Plus Oxaliplatin, Paclitaxel, or Enzalutamide in Participants With Advanced Solid Tumors (clinicaltrials.gov) - Nov 24, 2017
P1, N=123, Active, not recruiting, Sponsor: Genentech, Inc.
Not yet recruiting --> Recruiting Trial primary completion date: Oct 2017 --> Jun 2018
- BNC-101 / Carina Biotech
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer. (clinicaltrials.gov) - Nov 24, 2017
P1, N=21, Active, not recruiting, Sponsor: Bionomics Limited
Trial primary completion date: Oct 2017 --> Jun 2018 Recruiting --> Active, not recruiting | N=54 --> 21 | Trial primary completion date: Apr 2019 --> Jan 2018
- || spartalizumab (PDR001) / Novartis
Enrollment closed, Combination therapy, Metastases: PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer (clinicaltrials.gov) - Nov 24, 2017
P1, N=92, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
Recruiting --> Active, not recruiting | N=54 --> 21 | Trial primary completion date: Apr 2019 --> Jan 2018 Recruiting --> Active, not recruiting
- Imjudo (tremelimumab) / AstraZeneca, Pfizer, Imfinzi (durvalumab) / AstraZeneca
Trial primary completion date, Combination therapy, Metastases: Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Advanced Solid Tumors (clinicaltrials.gov) - Nov 22, 2017
P1, N=42, Recruiting, Sponsor: AstraZeneca
Recruiting --> Active, not recruiting Trial primary completion date: Jul 2020 --> Jun 2019
- | Trial primary completion date: A Phase II Study of Neoadjuvant FOLFIRINOX (clinicaltrials.gov) - Nov 22, 2017
P2, N=48, Recruiting, Sponsor: Safi Shahda
Trial primary completion date: Jul 2020 --> Jun 2019 Trial primary completion date: Dec 2017 --> Jun 2018
- | bortezomib / Generic mfg., thioguanine / Generic mfg.
Trial suspension: AALL1231: Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma (clinicaltrials.gov) - Nov 21, 2017
P3, N=1400, Suspended, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Dec 2017 --> Jun 2018 Recruiting --> Suspended
- | Stivarga (regorafenib) / Bayer
Enrollment open, Monotherapy, Metastases: Regorafenib Plus 5-Fluorouracil/Leucovorin Beyond Progression in mCRC (clinicaltrials.gov) - Nov 20, 2017
P2, N=15, Recruiting, Sponsor: Fox Chase Cancer Center
Recruiting --> Suspended Not yet recruiting --> Recruiting
- | Enrollment open, Enrollment change, Monotherapy, Mismatch repair, PD(L)-1 Biomarker, IO biomarker: Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (clinicaltrials.gov) - Nov 20, 2017
P3, N=347, Recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting | N=439 --> 347
- pazopanib / Generic mfg.
Enrollment change, Combination therapy: Study On Pazopanib When Given With FOLFOX6 (Fluorouracil, Oxaliplatin, Leucovorin) Or CapeOx (Capecitabine, Oxaliplatin) (clinicaltrials.gov) - Nov 18, 2017
P1, N=50, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Recruiting | N=439 --> 347 N=70 --> 50
- |||| Enrollment open: QUILT-3.060t: QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy (clinicaltrials.gov) - Nov 17, 2017
P1/2, N=80, Recruiting, Sponsor: NantKwest, Inc.
N=70 --> 50 Not yet recruiting --> Recruiting
- | bemarituzumab (AMG 552) / Amgen
New P1 trial, Metastases: FIGHT: A Study of Bemarituzumab (FPA144) Combined With Modified FOLFOX6 in Gastric/Gastroesophageal Cancer (clinicaltrials.gov) - Nov 17, 2017
P1, N=21, Not yet recruiting, Sponsor: Five Prime Therapeutics, Inc.
- | leucovorin calcium / Generic mfg., cisplatin / Generic mfg., epirubicin / Generic mfg.
Journal: Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance). (Pubmed Central) - Nov 16, 2017
In post hoc analyses, the effect of treatment seemed to be similar across all examined patient subgroups. Conclusion After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative chemoradiotherapy using a multiagent regimen of ECF before and after radiotherapy does not improve survival compared with standard FU and LV before and after radiotherapy.
- | Bavencio (avelumab) / EMD Serono
Enrollment open, Combination therapy, Metastases: Standard of Care Alone or in Combination With Ad-CEA Vaccine and Avelumab in People With Previously Untreated Metastatic Colorectal Cancer QUILT-2.004 (clinicaltrials.gov) - Nov 14, 2017
P2, N=81, Recruiting, Sponsor: National Cancer Institute (NCI)
Conclusion After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative chemoradiotherapy using a multiagent regimen of ECF before and after radiotherapy does not improve survival compared with standard FU and LV before and after radiotherapy. Suspended --> Recruiting
- | AiTan (rivoceranib) / HLB Bio Group
Trial initiation date, Metastases: XHZL: Safety and Efficacy Study of Chemotherapy Plus Apatinib as Second-line Therapy in Metastatic Colorectal Cancer (clinicaltrials.gov) - Nov 8, 2017
P2, N=50, Not yet recruiting, Sponsor: Wuhan Union Hospital, China
Suspended --> Recruiting Initiation date: Aug 2017 --> Dec 2017
- ||||| cabiralizumab (BMS-986227) / Ono Pharma, BMS, Opdivo (nivolumab) / BMS
New P2 trial: A Study of Cabiralizumab Given With Nivolumab With and Without Chemotherapy in Patients With Advanced Pancreatic Cancer (clinicaltrials.gov) - Nov 8, 2017
P2, N=160, Not yet recruiting, Sponsor: Bristol-Myers Squibb
- | leucovorin calcium / Generic mfg., cisplatin / Generic mfg., gemcitabine / Generic mfg.
Trial primary completion date, Metastases: Fluorouracil, Leucovorin, Gemcitabine, and Cisplatin in Treating Patients With Metastatic or Unresectable Adenocarcinoma of the Urothelium or Urachal Remnant (clinicaltrials.gov) - Nov 7, 2017
P2, N=46, Active, not recruiting, Sponsor: M.D. Anderson Cancer Center
Initiation date: Aug 2017 --> Dec 2017 Trial primary completion date: Feb 2018 --> Apr 2019
- |||| Graspa (eryaspase) / PHAXIAM Therap
Trial completion, Trial primary completion date, Metastases: Efficacy and Safety of L-asparaginase Encapsulated in RBC Combined With Gemcitabine or FOLFOX in 2nd Line for Progressive Metastatic Pancreatic Carcinoma (clinicaltrials.gov) - Nov 7, 2017
P2, N=141, Completed, Sponsor: ERYtech Pharma
Trial primary completion date: Feb 2018 --> Apr 2019 Active, not recruiting --> Completed | Trial primary completion date: Oct 2016 --> Feb 2017